BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26277433)

  • 1. Evaluation of a 36 Gy elective node irradiation dose in anal cancer.
    Lépinoy A; Lescut N; Puyraveau M; Caubet M; Boustani J; Lakkis Z; Fantoli M; Buffet-Miny J; Kim S; Bednarek C; Maingon P; Créhange G; Bosset JF
    Radiother Oncol; 2015 Aug; 116(2):197-201. PubMed ID: 26277433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
    Ferrigno R; Nakamura RA; Dos Santos Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV; Filho WJ; Lopes A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1136-42. PubMed ID: 15752894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-five-year experience with radical chemoradiation for anal cancer.
    Tomaszewski JM; Link E; Leong T; Heriot A; Vazquez M; Chander S; Chu J; Foo M; Lee MT; Lynch CA; Mackay J; Michael M; Tran P; Ngan SY
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):552-8. PubMed ID: 22019078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots?
    Henkenberens C; Meinecke D; Michael S; Bremer M; Christiansen H
    Strahlenther Onkol; 2015 Nov; 191(11):845-54. PubMed ID: 26307627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
    James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
    Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Squamous cell carcinoma of the anal margin: the university of Florida experience.
    Balamucki CJ; Zlotecki RA; Rout WR; Newlin HE; Morris CG; Kirwan JM; George TJ; Mendenhall WM
    Am J Clin Oncol; 2011 Aug; 34(4):406-10. PubMed ID: 20881476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
    Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
    Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
    Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
    Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
    J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
    El-Hadaad HA; Wahba HA; Roshdy S
    J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
    Glynne-Jones R; Sebag-Montefiore D; Meadows HM; Cunningham D; Begum R; Adab F; Benstead K; Harte RJ; Stewart J; Beare S; Hackshaw A; Kadalayil L;
    Lancet Oncol; 2017 Mar; 18(3):347-356. PubMed ID: 28209296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined chemoradiation therapy for anal cancer. A report of 56 cases.
    Doci R; Zucali R; Bombelli L; Montalto F; Lamonica G
    Ann Surg; 1992 Feb; 215(2):150-6. PubMed ID: 1546901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
    Hsu FM; Lee JM; Huang PM; Lin CC; Hsu CH; Tsai YC; Lee YC; Chia-Hsien Cheng J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e593-9. PubMed ID: 21658851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer.
    Lee IH; Lee SJ; Kang BW; Chae YS; Baek D; Hwang S; Kim HJ; Park SY; Park JS; Choi GS; Kim JC; Kim JG
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1263-1267. PubMed ID: 27830320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
    Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
    Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
    Bentzen AG; Guren MG; Wanderås EH; Frykholm G; Tveit KM; Wilsgaard T; Dahl O; Balteskard L
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e173-80. PubMed ID: 22436791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control.
    Zilli T; Betz M; Bieri S; Ris F; Roche B; Roth AD; Allal AS
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):60-6. PubMed ID: 23608237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidermoid carcinomas of the anal canal treated with definitive radiation therapy in a series of 305 patients].
    Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Houry S; Gallot D; Parc R; Huang R; Qu SH; Pène F; Schlienger M
    Cancer Radiother; 2003 Aug; 7(4):237-53. PubMed ID: 12914857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.